5:50 PM
 | 
Nov 05, 2013
 |  BC Extra  |  Financial News

Regeneron beats Street, ups Eylea guidance

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gained $20.62 to $302.32 on Tuesday after reporting 3Q13 earnings that beat the Street. The company's 3Q13 GAAP diluted EPS was $1.25, down from $1.72 in 3Q12 but beating the Street's estimate of $0.90. Revenues in the...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >